---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000162"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:24:21.115429+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering

## Summary
- Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.
- Public offering priced at $1.50/unit (common + Series A/B warrants); net proceeds ~$6.3M, closed Nov 12.
- Frederick Pierce (Decoy CEO) appointed CEO, replacing Mark Rosenblum who remains CFO; Dr. Barbara Hibner as CSO, Peter Marschel as CBO.
- Board change: Pierce appointed Class II director; Bruce McCreedy resigned, not due to any disagreement.
- Warrants: Series A (5-yr term, $1.50 exercise), Series B (1-yr term, $1.50), Pre-funded ($0.0001). Representative warrants also issued.

## SEC filing metadata
- accession: 0001615219-25-000162
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000162/0001615219-25-000162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000162/flks-20251111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000162
- JSON: https://secwatch.observer/filing/0001615219-25-000162.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.